Nucleic Acid Quantification, Mutation Enrichment Technologies & Streamlining Genotyping
Posted 30th January 2019 by Kieran Chambers
In just two years’ time, the digital PCR and qPCR market is set to be worth an estimated $4.94 billion. Dedicated sessions at the 4BIO Summit covered topics such as gene expression analysis, liquid biopsies and high-throughput screening. We have made the following presentation slides from Hendrik Emons, Naomi Park & Mike Makrigiorgos available.
|Hendrik Emons gives an overview on the current achievable analytical performance characteristics of dPCR methods, presented in combination with points for attention and limitations of corresponding analytical procedures.|
|Naomi Park from the Wellcome Sanger Institute discusses the new and alternative bespoke high-throughput amplicon sequencing pipeline which requires no up-front sample quantification or normalisation.|
Novel digital PCR and mutation enrichment technologies for the analysis of clinically relevant DNA alterations in liquid biopsies
|Dr Mike Makrigiorgos talks through the increasing interest in treatment assessment using liquid biopsy and circulating DNA.|
Want to read more on PCR and qPCR? Good news! Our resources page is packed full of slides and presentation videos, why not take a look now?
Leave a Reply